Novo Nordisk’s stock slumps after failed trial — adding to the company’s woes
At a glance
The Danish healthcare company’s stock slumped on Friday after it announced the Phase 3 trial failure.
- Primary source
- MarketWatch.com - Top Stories — Read original article
- Published
- Topic
- Finance
The Danish healthcare company’s stock slumped on Friday after it announced the Phase 3 trial failure.
This summary comes from MarketWatch.com - Top Stories. Read the full article at the original source.
References
More in Finance
If Social Security’s funding crisis is the elephant in the room, this is the mouse everyone has overlooked. You have been warned.
“Delaying Social Security until 70 results in an increased monthly payment — and that comes with proportionally higher cost-of-living adjustments.”
‘We have always been civil’: My sister refuses to replace me as executor. Can I step down before she dies?
“I haven’t seen my sister since our mother’s funeral more than 20 years ago.”
Goldman traders are on pace for a record year. A close-up look at how they're doing it
In a new interview with CNBC, a Goldman exec breaks down what's driving stocks, where markets are headed, and how the bank’s equities desk fuels its growth.
Let’s elect candidates who will make the wealthy pay taxes
We can use some of those revenues to make Social Security contributions more equitable.